2Pfaller MA, Diekema DJ, Jones RN,et al. Trends in antifungal susceptibility of Candida spp isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000[J]. J Clin Microbiol, 2002,40(3): 852-856.
3Doczi I, Dosa E, Hajdu E,et al. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000[J]. J Med Microbiol, 2002,51 : 677-681.
4Verweli PE, Erjaver Z, Sluiters W, etal. Detection of antigen in sera of patients with invasive aspergillosis[J]. J Clin Microbiol, 1998,36 (6) :1612-1616.
5Gharnoum MA, Rex JH, Galgian JN. Susceptibility testing of fungi. Current status of correlation of in vitro data with clinical outcome[J]. J Clin Microbiol, 1996, 34(3):489-495.
6Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program[J]. J Clin Microbiol, 1998,36(7) : 1886-1889.
7Marco F, Pfaller MA, Messer S, et al. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp [J]. Antimicrob Agents Chemother, 1998,42(1) : 161-163.
8Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center[J]. Antimicrob Agents Chemother, 1998, 42(4) : 734-738.
9National Committee for Clinical Latoratory Standards. Minutes US NCCLS antifungal susceptibility Subcommittee meeting on interpretive breakpoints [S]. NCCLS,2002. Villanova, PA.
